Cover Image
市場調查報告書

經皮藥物遞輸系統的全球市場(用途,技術,地區):規模,佔有率,全球趨勢,企業簡介,考察,分析,調查,報告,機會,市場區隔,預測

Transdermal Drug Delivery Systems Market by Type of Delivery System [Passive (Matrix System and Reservoir System), Active [Structure Based, Electrical Based, and Others] and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 529338
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
經皮藥物遞輸系統的全球市場(用途,技術,地區):規模,佔有率,全球趨勢,企業簡介,考察,分析,調查,報告,機會,市場區隔,預測 Transdermal Drug Delivery Systems Market by Type of Delivery System [Passive (Matrix System and Reservoir System), Active [Structure Based, Electrical Based, and Others] and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年07月01日 內容資訊: 英文 150 Pages
簡介

本報告提供全球經皮藥物遞輸系統市場相關調查分析,彙整市場概要,遞送系統類別,各用途,各地區的考察,主要企業簡介等相關資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 市場佔有率分析
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會

第4章 經皮藥物遞輸系統市場:遞送系統類別

  • 概要
  • 被動式遞送系統
  • 主動式遞送系統

第5章 經皮藥物遞輸系統市場:各用途

  • 概要
  • 止痛藥
  • 荷爾蒙補充療法
  • 高血壓
  • 暈車
  • 戒煙
  • 其他

第6章 經皮藥物遞輸系統市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美/中東/非洲

第7章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 17485

Transdermal route is a promising alternative for oral and injectable drug delivery wherein skin is the primary site for drug administration. This drug delivery system offers certain benefits, such as non-invasiveness, controlled & complete drug delivery from the dosage form and improved patient compliance. Transdermal patches, ointments, gel and implants are the popular transdermal drug delivery systems. Over the past few years, transdermal patches have gained significant importance. The transdermal drug delivery market has witnessed vertical growth over the past few decades and this trend is expected to continue during the forecast period. This growth would be driven by the steadily growing number of transdermal drug delivery products in the market resulting from the widespread adoption of these products by consumers. Johnson and Johnson, Acrux, Antares Pharma, Dermatrends Inc., Bayer HealthCare Pharmaceuticals, Novartis, Janssen Pharmaceuticals Inc. and Durect Corporation are some of the key leaders in the global transdermal drug delivery systems market. Recently, NuPathe Inc. received FDA clearance for their transdermal patch, Zeltrix. It is a single use preparation intended for the treatment of migraine pain.

The global transdermal drug delivery systems market is segmented on the basis of application, technology and geography. The application segment is further categorized into CNS, Pain Management, Hormone, Cardiovascular and Others. Transdermal patches for pain management and hormonal drug delivery dominate the market. Vivelle-dot and Climara are estrogen patches currently available in the market, offered by Novartis and Bayer HealthCare Pharmaceuticals, respectively. They are used in the delivery of estradiol for hormone replacement therapy. Based on technology, the global transdermal drug delivery systems market is segmented into Electroporation, Electric current, Lontophoresis, Radio Frequency, Microporation, Thermal, Mechanical arrays and Ultrasound. These technologies form an efficacious drug delivery system by improving the drug distribution pattern across the skin. Geographically, the global transdermal drug delivery systems market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominate the global market due to extensive R&D efforts and presence of numerous approved transdermal products.

KEY BENEFITS:

This report offers the following benefits in particular:

  • In-depth coverage of the global transdermal drug delivery systems market including drivers, restraints and opportunities would help professionals to better understand market behavior
  • Detailed study of the strategies of key leaders, partnerships and acquisitions in the global transdermal drug delivery systems market would be informative for professionals in the corporate sector
  • Porter's Five Forces analysis examines the competitive structure of the global transdermal drug delivery systems market and would assist market strategists in making decisions.
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the global transdermal drug delivery systems market

KEY MARKET SEGMENTS:

The global transdermal drug delivery systems market is segmented into three major categories: application, technology and geography.

MARKET BY APPLICATION

  • CNS
  • Pain Management
  • Hormone
  • Cardiovascular
  • Others

MARKET BY TECHNOLOGY

  • Electroporation
  • Electric current
  • Lontophoresis
  • Radio Frequency
  • Microporation
  • Thermal
  • Mechanical arrays
  • Ultrasound

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.1. KEY BENEFITS
  • 1.2. KEY MARKET SEGMENTS
  • 1.3. RESEARCH METHODOLOGY
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
      • 3.2.2.1. Competitive intelligence of companies and their strategies
  • 3.3. MARKET SHARE ANALYSIS, 2016
  • 3.4. MARKET DYNAMICS
    • 3.4.1. Drivers
      • 3.4.1.1. Rising geriatric population
      • 3.4.1.2. Increasing prevalence of chronic disorders
      • 3.4.1.3. Rise in adoption of third-generation delivery systems
    • 3.4.2. Restraints
      • 3.4.2.1. Side-effects of the systems
    • 3.4.3. Opportunities
      • 3.4.3.1. Emerging nations

CHAPTER 4: TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. PASSIVE DELIVERY SYSTEM
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
      • 4.2.3.1. Matrix delivery system
      • 4.2.3.1.1. Market size and forecast
      • 4.2.3.2. Reservoir delivery system
      • 4.2.3.2.1. Market size and forecast
  • 4.3. ACTIVE DELIVERY SYSTEM
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
      • 4.3.3.1. Structure-based drug delivery system
      • 4.3.3.1.1. Market size and forecast
      • 4.3.3.2. Electrically-based drug delivery system
      • 4.3.3.2.1. Market size and forecast
      • 4.3.3.2.2. Iontophoresis
      • 4.3.3.2.2.1. Market size and forecast
      • 4.3.3.2.3. Electroporation
      • 4.3.3.2.3.1. Market size and forecast
      • 4.3.3.2.4. Sonophoresis
      • 4.3.3.2.4.1. Market size and forecast
      • 4.3.3.3. Other
      • 4.3.3.3.1. Market size and forecast

CHAPTER 5: TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. ANALGESICS
    • 5.2.1. Market size and forecast
  • 5.3. HORMONE REPLACEMENT THERAPY
    • 5.3.1. Market size and forecast
  • 5.4. HYPERTENSION
    • 5.4.1. Market size and forecast
  • 5.5. MOTION SICKNESS
    • 5.5.1. Market size and forecast
  • 5.6. SMOKING CESSATION
    • 5.6.1. Market size and forecast
  • 5.7. OTHERS
    • 5.7.1. Market size and forecast

CHAPTER 6: TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. NORTH AMERICA
    • 6.2.1. Key market trends
    • 6.2.2. Growth factors and opportunities
    • 6.2.3. Market size and forecast
  • 6.3. EUROPE
    • 6.3.1. Key market trends
    • 6.3.2. Growth factors and opportunities
    • 6.3.3. Market size and forecast
  • 6.4. ASIA-PACIFIC
    • 6.4.1. Key market trends
    • 6.4.2. Growth factors and opportunities
    • 6.4.3. Market size and forecast
  • 6.5. LAMEA
    • 6.5.1. Key market trends
    • 6.5.2. Growth factors and opportunities
    • 6.5.3. Market size and forecast

CHAPTER 7: COMPANY PROFILES

  • 7.1. ACRUX LIMITED
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Business performance
    • 7.1.5. Key strategic moves and developments
    • 7.1.6. Strategy share (%)
  • 7.2. BAYER AG
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Business performance
    • 7.2.5. Key strategic moves and developments
    • 7.2.6. Strategy share (%)
  • 7.3. BOEHRINGER INGELHEIM GMBH
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Business performance
    • 7.3.5. Key strategic moves and developments
    • 7.3.6. Strategy share (%)
  • 7.4. BRISTOL-MYERS SQUIBB COMPANY
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Business performance
    • 7.4.5. Key strategic moves and developments
    • 7.4.6. Strategy share (%)
  • 7.5. ECHO THERAPEUTICS, INC.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Business performance
    • 7.5.5. Key strategic moves and developments
    • 7.5.6. Strategy share (%)
  • 7.6. ENDO PHARMACEUTICALS INC.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Business performance
    • 7.6.5. Key strategic moves and developments
    • 7.6.6. Strategy share (%)
  • 7.7. GLAXOSMITHKLINE PLC
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Business performance
    • 7.7.5. Key strategic moves and developments
    • 7.7.6. Strategy share (%)
  • 7.8. JOHNSON & JOHNSON
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Business performance
    • 7.8.5. Key strategic moves and developments
    • 7.8.6. Strategy share (%)
  • 7.9. MYLAN N.V.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Business performance
    • 7.9.5. Key strategic moves and developments
    • 7.9.6. Strategy share (%)
  • 7.10. NOVARTIS AG
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Business performance
    • 7.10.5. Key strategic moves and developments
    • 7.10.6. Strategy share (%)

List of Tables

  • TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM, 2016-2023 ($MILLION)
  • TABLE 2. GLOBAL PASSIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 3. PASSIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 ($MILLION)
  • TABLE 4. NORTH AMERICA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 5. EUROPE PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 6. ASIA-PACIFIC PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 7. LAMEA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 8. GLOBAL ACTIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 9. ACTIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 ($MILLION)
  • TABLE 10. NORTH AMERICA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 11. EUROPE ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 12. ASIA-PACIFIC ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 13. LAMEA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 14. GLOBAL ELECTRICALLY-BASED DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ANALGESICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR HORMONE REPLACEMENT THERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ISCHEMIC STROKE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR MOTION SICKNESS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 20. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR SMOKING CESSATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 22. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 23. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 24. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 25. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 27. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 28. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 29. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
  • TABLE 30. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 31. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 32. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
  • TABLE 33. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
  • TABLE 34. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
  • TABLE 36. ACRUX: COMPANY SNAPSHOT
  • TABLE 37. ACRUX: OPERATING SEGMENTS
  • TABLE 38. BAYER: COMPANY SNAPSHOT
  • TABLE 39. BAYER: OPERATING SEGMENTS
  • TABLE 40. BOEHRINGER: COMPANY SNAPSHOT
  • TABLE 41. BOEHRINGER: OPERATING SEGMENTS
  • TABLE 42. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 43. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 44. ECHO: COMPANY SNAPSHOT
  • TABLE 45. ECHO: OPERATING SEGMENTS
  • TABLE 46. ENDO: COMPANY SNAPSHOT
  • TABLE 47. ENDO: OPERATING SEGMENTS
  • TABLE 48. GSK: COMPANY SNAPSHOT
  • TABLE 49. GSK: OPERATING SEGMENTS
  • TABLE 50. J&J: COMPANY SNAPSHOT
  • TABLE 51. J&J: OPERATING SEGMENTS
  • TABLE 52. MYLAN: COMPANY SNAPSHOT
  • TABLE 53. MYLAN: OPERATING SEGMENTS
  • TABLE 54. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 55. NOVARTIS: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, 2016-2023
  • FIGURE 2. SEGMENTATION OF GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
  • FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
  • FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2016)
  • FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
  • FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIGURE 7. TOP COMPANIES AND THEIR STRATEGIES
  • FIGURE 8. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
  • FIGURE 9. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
  • FIGURE 10. MARKET SHARE ANALYSIS, 2016
  • FIGURE 11. IMPACT ANALYSIS, TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
  • FIGURE 12. GLOBAL MATRIX DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 13. GLOBAL RESERVOIR DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
  • FIGURE 14. GLOBAL STRUCTURE-BASED DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. GLOBAL IONTOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. GLOBAL ELECTROPORATION DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. GLOBAL SONOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. GLOBAL OTHER DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. ACRUX: FINANCIALS
  • FIGURE 20. BAYER: FINANCIALS
  • FIGURE 21. BOEHRINGER: FINANCIALS
  • FIGURE 22. BRISTOL-MYERS SQUIBB: FINANCIALS
  • FIGURE 23. ECHO: FINANCIALS
  • FIGURE 24. ENDO: FINANCIALS
  • FIGURE 25. GSK: FINANCIALS
  • FIGURE 26. J&J: FINANCIALS
  • FIGURE 27. MYLAN: FINANCIALS
  • FIGURE 28. NOVARTIS: FINANCIALS
Back to Top